Nuvamid SA
🇨ðŸ‡Switzerland
Study of the Safety, Tolerability, and Pharmacokinetics of NUV001 Administered Orally to Healthy Adult Participants
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: NUV001 active cohort 1Drug: NUV001 placebo cohort 1Drug: NUV001 active cohort 2Drug: NUV001 placebo cohort 2Drug: NUV001 placebo cohort 3Drug: NUV001 active cohort 3Drug: NUV001 placebo cohort 4Drug: NUV001 active cohort 4
- First Posted Date
- 2023-11-15
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Nuvamid SA
- Target Recruit Count
- 32
- Registration Number
- NCT06133478
- Locations
- 🇺🇸
Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States
© Copyright 2025. All Rights Reserved by MedPath